Neuro-Oncology

Published by: Oxford University Press  

People

  1. De Angelis
    De Angelis
  2. Dunkel
    Dunkel
  3. Mellinghoff
    Mellinghoff
  4. Karajannis
    Karajannis
  5. Souweidane
    Souweidane
  6. Rosenblum
    Rosenblum
  7. Kaley
    Kaley
  8. Pentsova
    Pentsova
  9. Khakoo
    Khakoo
  10. Kramer
    Kramer

Groups

  1. Tow Center for Developmental Oncology (TCDO) (238)
  2. Pediatrics, Department of (233)
  3. GSK Faculty (230)
  4. Neuro-Oncology Service (175)
  5. Survivorship Research (149)
  6. Human Oncology and Pathogenesis Program (129)
  7. Radiology, Department of (121)
  8. Neuroradiology Service (96)
  9. Department of Medicine (95)
  10. Department of Pathology and Laboratory Medicine (94)
Search Within
Formats
  1. Meeting Abstract (667)
  2. Journal Article (144)
  3. Review (14)
  4. Editorial (11)
  5. Guidelines (5)
  6. Correspondence (1)
  7. Research Letter (1)
Groups
  1. Tow Center for Developmental Oncology (TCDO) (238)
  2. Pediatrics, Department of (233)
  3. GSK Faculty (230)
  4. Neuro-Oncology Service (175)
  5. Survivorship Research (149)
  6. Human Oncology and Pathogenesis Program (129)

More Groups

People
  1. Lisa De Angelis (109)
  2. Ingo Mellinghoff (84)
  3. Ira Dunkel (84)
  4. Matthias Karajannis (65)
  5. Antonio Omuro (63)
  6. Lauren Abrey (63)

More People

Years
  1. 2025 (1)
  2. 2024 (67)
  3. 2023 (53)
  4. 2022 (62)
  5. 2021 (35)
  6. 2020 (66)

More Years

Publishers
  1. Oxford University Press (843)

Results (843)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • NANO-LM: An updated scorecard for the clinical assessment of patients with leptomeningeal metastases
    Journal Article

    Le Rhun, E.; Nayak, L.; Lim-Fat, M. J.; Rudà, R.; Pentsova, E.; Forsyth, P.; O'Brien, B. J.; Preusser, M.; Kumthekar, P.; Brandsma, D.; more...
    Neuro-Oncology (2025)

    Fulltext@MSK | Save
  • Targeted delivery of napabucasin with radiotherapy improves outcomes in diffuse midline glioma
    Journal Article

    Gallitto, M.; Zhang, X.; De Los Santos, G.; Wei, H. J.; Fernández, E. C.; Duan, S. F.; Sedor, G.; Yoh, N.; Kokossis, D.; Angel, J. C.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with adult-type diffuse glioma with an IDH1/2 mutation (INDIGO): Updated efficacy results
    Meeting Abstract

    Mellinghoff, I. K.; van den Bent, M. J.; Touat, M.; Blumenthal, D. T.; Peters, K. B.; Ellingson, B. M.; Clarke, J. L.; Mendez, J.; Yust-Katz, S.; Mason, W. P.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with TRK fusion primary central nervous system (CNS) tumors: An updated analysis
    Meeting Abstract

    Perreault, S.; Spano, J. P.; Nilsson, A.; Deyell, R. J.; Doz, F.; Geoerger, B.; Gumus, M.; Lassen, U. N.; Nysom, K.; Valero-Arrese, L.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Evaluation of paxalisib in GBM AGILE phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Mellinghoff, I. K.; Cloughesy, T.; Alexander, B.; Berry, D. A.; Buxton, M.; Cavenee, W.; Colman, H.; de Groot, J.; Ellingson, B. M.; Gordon, G. B.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of AZD1390 + radiation therapy for glioblastoma
    Meeting Abstract

    Wen, P.; Yang, J. T.; Imber, B. S.; Drappatz, J.; Jena, R.; Forst, D.; Zukas, A.; Short, S. C.; Fan, C.; Trigg, W.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Outcome of patients with recurrent medulloblastoma and ependymoma treated with pembrolizumab, an immune checkpoint inhibitor: A Pediatric Brain Tumor Consortium study (PBTC045)
    Meeting Abstract

    Hwang, E.; Kilburn, L.; Mitchell, D.; Lin, T.; Poussaint, T. Y.; Robinson, G.; Gajjar, A.; Lenzen, A.; Dorris, K.; Robison, N.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
    Meeting Abstract

    Lassman, A.; Alexander, B.; Berry, D.; Berry, N.; Buxton, M.; Colman, H.; Gan, H.; de Groot, J.; de la Fuente, M.; Drappatz, J.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • Alliance A071401: Genomically guided phase II trial of abemaciclib in patients with grade 2/3 meningiomas harboring somatic NF2 or CDK pathway alterations
    Meeting Abstract

    Brastianos, P.; Dooley, K.; Geyer, S.; Gerstner, E.; Kaufmann, T.; Iafrate, A. J.; Martinez-Lage, M.; Milhem, M.; Welch, M.; Kaley, T.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save
  • A phase 1, safety lead-in and randomized, open-label, perioperative study of vorasidenib combined with pembrolizumab in recurrent or progressive enhancing IDH1 mutant glioma: Trial in progress
    Meeting Abstract

    Wen, P. T.; de la Fuente, M.; Kumthekar, P.; Peters, K.; Clarke, J.; de Groot, J.; Arrillaga-Romany, I.; Puduvalli, V.; Mellinghoff, I.; Chong, R.; more...
    Neuro-Oncology (2024)

    Fulltext@MSK | Save

    • Neuro-Oncology – authorized name for:

    Name ISSN / ISBN Publisher
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press On Behalf of the Society for Neuro Oncology
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-oncology 15235866 Unknown
    Neuro-Oncology 15228517 The Author(s) 2024
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 15228517 The Author(s)
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 15228517 Oxford University Press On Behalf of the Society for Neuro Oncology
    Neuro-Oncology 1522-8517 Carden Jennings Publ Co Ltd
    Neuro-Oncology 1522-8517 Duke University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 15228517 Unknown
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 15228517 The Author(s) 2023
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press
    Neuro-oncology 15235866 Oxford University Press On Behalf of the Society for Neuro Oncology
    Neuro-Oncology 1522-8517 Duke University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1523-5866 Oxford University Press On Behalf of the Society for Neuro Oncology
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Oxford University Press
    Neuro-Oncology 1522-8517 Society for Neuro Oncology